Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer
- 15 April 1989
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (4) , 651-654
- https://doi.org/10.1016/0277-5379(89)90200-9
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist d-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancerJournal of Endocrinology, 1986
- The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancerBritish Journal of Cancer, 1986
- Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancerJournal of Steroid Biochemistry, 1985
- Biodegradable polymers for the sustained release of peptidesBiochemical Society Transactions, 1985
- Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancerJournal of Steroid Biochemistry, 1984
- Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.BMJ, 1981
- Randomized Clinical Trial of Diethylstilbestrol versus Tamoxifen in Postmenopausal Women with Advanced Breast CancerNew England Journal of Medicine, 1981
- Antihormone treatment of stage IV breast cancerCancer, 1979
- Antiestrogens in treatment of breast cancerCancer, 1977
- Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course.BMJ, 1977